Biodesix Inc., a Buolder, Co.-based molecular diagnostics company that researches, develops and commercializes rapid, blood-based tests for precision medicine in oncology, raised another $11m in Series E financing.
Existing Biodesix shareholders provided all of the new capital. It added to the $27 million series E shares sold from 2013 through 2015 for total proceeds of $38m.
The investment will be used for ongoing new product development and expansion of commercial efforts to support Biodesix’ commercialized products, VeriStrat® and GeneStrat™, as well as new product launches in 2015 – 2016.
Led by David Brunel, Chief Executive Officer, Biodesix is a molecular diagnostics company advancing the development of innovative blood-based tests – GeneStrat™ and VeriStrat® – for precision medicine in oncology.
VeriStrat is a blood-based serum protein test that provides diagnostic information on disease aggressiveness and helps physicians guide therapy for patients with advanced non-small cell lung cancer (NSCLC) while GeneStrat is a targeted, blood-based mutation test for patients with advanced cancer.